Oncolin Therapeutics Announces Its New 'Super Cell Blocker', ONC-127, Has Shown Effectiveness In Treating Cancer
Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that its new Super Cell Blocker, ONC-127, has been effective in treating animals that have been implanted with human tumors in their brains. This technology has extended the life of animals in a preclinical environment.
Early Warning' For Oral Cancer Now Covered Under UnitedHealthcare Specialty Benefits Dental Plans
UnitedHealthcare Specialty Benefits now provides coverage under all of its insured dental plans for a new oral cancer screening test for potential abnormalities inside the mouth, including premalignant lesions and oral cancer. The test, which uses light-contrast technology, can improve a dentist's ability to identify, evaluate and monitor lesions that are difficult to see using visual inspection under conventional lighting.
Memory Pharmaceuticals Highlights Progress With Key Programs At Its R D Day
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans.
Rosetta Genomics To Present Multiple Posters At The 44th Annual Meeting Of The American Society Of Clinical Oncology ASCO
Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website.
Significant Anti-Tumor Activity Of NKTR-102 In Patients With Refractory Solid Tumors; Interim Data Published In ASCO 2008 Proceedings
Nektar Therapeutics (Nasdaq: NKTR) announced initial results from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors. The study also demonstrates that Nektar's small molecule PEGylation technology produced an increase in SN38 exposure that was up to six-fold higher than the exposure previously reported with irinotecan at equivalent doses.
Nexavar Significantly Improves Overall Survival By 47 Percent In Asia Pacific Liver Cancer Study
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo.
New Treatment Implications For Ovarian Cancer Unveiled
New research findings from a top clinical investigator at The Cancer Institute of New Jersey (CINJ) indicate the potential for more targeted treatment of ovarian cancer, which is expected to claim more than 15, 000 lives nationwide this year, with 480 in New Jersey.
Diagnostic Accuracy May Not Be Improved By PET Imaging In Early Head And Neck Cancer
Positron emission tomography with a radioactive tracer (18F-FDG PET) may not improve the detection of small metastases in patients with head and neck cancer who have no clinical evidence of disease in neighboring lymph nodes, according to a meta-analysis published online May 13 in the Journal of the National Cancer Institute.
ASCO Names Jay R. Harris, MD, Gianni Bonadonna Breast Cancer Award Winner
The American Society of Clinical Oncology (ASCO) announced the winner of the annual Gianni Bonadonna Breast Cancer Award. Jay R. Harris, MD, will accept the award and present his award lecture, "Local Treatment of Breast Cancer: Looking Backward to Gaze Forward, " at the upcoming 2008 Breast Cancer Symposium, being held September 5-7 in Washington, DC.
News From The Journal Of The National Cancer Institute
Familial Breast Cancer Risk Continues Throughout a Woman's LifeWomen who have a sister diagnosed with breast cancer are at an increased risk of developing the disease throughout their lives. The increased risk is most pronounced in younger women, regardless of the age at which the first sister was diagnosed.